Tag Archives: Sativex

December, 2017

  • 15 December

    GW Pharma Reacquires Full Rights to Develop and Commercialize Sativex in the US

    London, UK, 13 Dec 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announces the termination of its previous license agreement with Otsuka Pharmaceutical Co., Ltd. in relation to Sativex®(nabiximols) in the U.S. …

October, 2015

  • 27 October

    GW and Otsuka Announce Phase 3 Results from its Sativex Trials

    LONDON and PRINCETON, N.J., Oct. 27, 2015 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (AIM:GWP) (“GW”) and Otsuka Pharmaceutical Development & Commercialization, Inc. (“Otsuka”), today reported top-line results from the remaining two Phase 3 trials for the investigational product Sativex® in the treatment of pain in patients with advanced cancer …